India is the world's largest supplier of generic drugs, and its fast-growing US$42 billion pharmaceutical industry plays a significant role in providing affordable healthcare to millions of people worldwide.

While evidence from psilocybin studies in rodents demonstrates long–term coping strategy and cognitive function behavioural effects that can be compared to those of traditional antidepressant treatments, a “gold-standard” protocol for assessing the behavioural effects of psychedelics has yet to be established.